Post-hoc analysis of Phase 3 study to highlight transfusion avoidance results of SB12 compared to reference eculizumab-treated groups INCHEON, Korea, May .
These results in the subgroup analysis, seen among individuals who were both identified as Asian and non-Asian, align with data published previously in the overall population.
Share this article
Share this article
ResearchAndMarkets.com s offering.
This report provides comprehensive insight on clinical and non-clinical factors that are driving the global C5 Complement Inhibitors market and its impact on the global pharmaceutical market landscape. The report has been prepared in a view to deeply profile the current market trends along with the sales insight on 3 commercially available C5 Complement Inhibitors with their regional level revenue, market share and the clinical profile.
Report Highlights:
Global C5 Complement Inhibitors Drug Market Absolute Growth: 65% (2017 -2020)
Global C5 Complement Inhibitors Drug Market Growth In 2020: 21% (> USD 5 Billion)
Commercially Available C5 Complement Inhibitors Drugs: 3 (Soliris, Ultomiris & Elizaria)
Worldwide C5 Complement Inhibitors Drug Industry to 2026 - Detailed Profiles of Current Market Trends prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.